First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

BACKGROUND: Here, we report the results of the Japanese subgroup of the phase 3 KEYNOTE-048 study of pembrolizumab alone, pembrolizumab plus platinum and 5-fluorouracil (pembrolizumab–chemotherapy), or cetuximab plus platinum and 5-fluorouracil (EXTREME) in previously untreated recurrent/metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Shunji, Oridate, Nobuhiko, Tanaka, Kaoru, Shimizu, Yasushi, Fujimoto, Yasushi, Matsumoto, Koji, Yokota, Tomoya, Yamazaki, Tomoko, Takahashi, Masanobu, Ueda, Tsutomu, Hanai, Nobuhiro, Yamaguchi, Hironori, Hara, Hiroki, Yoshizaki, Tomokazu, Yasumatsu, Ryuji, Nakayama, Masahiro, Shiga, Kiyoto, Fujii, Takashi, Mitsugi, Kenji, Takahashi, Kenichi, Nohata, Nijiro, Gumuscu, Burak, Swaby, Ramona F., Tahara, Makato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700657/
https://www.ncbi.nlm.nih.gov/pubmed/36264378
http://dx.doi.org/10.1007/s10147-022-02233-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700657/
https://www.ncbi.nlm.nih.gov/pubmed/36264378
http://dx.doi.org/10.1007/s10147-022-02233-6

Ejemplares similares